HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy

Today's guest post comes from Nareda Mills, President of Patient Solutions at Inizio Engage. Nareda examines how growing access complexity is reshaping specialty commercialization. She explores the emerging role of Non-Dispensing Pharmacies (NDPs) and argues that by improving coordination, visibilit

By Drug Channels · Jun 18, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line
The WeekFiercePharma ↗
4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line
Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treat…
Jun 18, 2026
F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test
The WeekFierceBiotech ↗
F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test
F2G and Shionogi have released phase 3 data for the oral antifungal drug olorofim, demonstrating its non-infer…
Jun 18, 2026
FDA signals openness to Moderna flu shot; UniQure and Lilly make moves
The WeekBriefing
FDA signals openness to Moderna flu shot; UniQure and Lilly make moves
Regulators appear receptive to Moderna's flu vaccine, UniQure prepares a Huntington's filing, and Lilly announ…
Jun 18, 2026